Prescription Drug Prices: Analysis of Canada's Patented Medicine Prices Review Board
HRD-93-51
Published: Feb 17, 1993. Publicly Released: Feb 22, 1993.
Skip to Highlights
Highlights
Pursuant to a congressional request, GAO: (1) described the purpose and structure of Canada's Patented Medicine Prices Review Board as well as its guidelines and procedures, especially those used to determine if a drug price is excessive; and (2) summarized the evidence about the effects of the Board's actions on the prices of new drugs, on price increases for existing drugs, and on pharmaceutical research and development.
Full Report
Topics
Comparative analysisCost analysisDrugsForeign governmentsHealth care cost controlPharmaceutical industryPharmacological researchPrice fixingPrice regulationResearch and development costs